Synchron Raises $75M Series C Led By Arch Venture Partners To Advance Endovascular Brain-Computer Interface
Amount Raised
$75 Million
Round Type
Series C
BrooklynOtherBiotechnologyHealth CareMedical Equipment ManufacturingInvestors
Description
Synchron, the endovascular brain-computer interface (BCI) company, announced today an oversubscribed $75 million Series C financing round led by ARCH Venture Partners. Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors. Existing investors, including Khosla Ventures, NeuroTechnology Investors, METIS, Forepont Capital Partners, ID8 Investments, Shanda Group and University of Melbourne participated in the round. The Series C funding brings the total amount raised since inception to $145 million.
Quick answer
Synchron raised $75 Million in a Series C round, dated December 15, 2022. Investors: Id8 Investments, Forepont Capital Partners, Neuro Technology Investors, Khosla Ventures, Moore Strategic Ventures, Alumni Ventures and ARCH Venture Partners. Synchron is based in Brooklyn, New York, United States.
- How much did Synchron raise?
- Synchron raised $75 Million in a Series C round on December 15, 2022.
- Who invested in Synchron?
- Id8 Investments, Forepont Capital Partners, Neuro Technology Investors, Khosla Ventures, Moore Strategic Ventures, Alumni Ventures and ARCH Venture Partners are named as investors in this round.
- What does Synchron do?
- Synchron is developing implantable neurotechnology to unlock the brain and solve unmet medical needs at scale
- Where is Synchron based and how big is it?
- Synchron is based in Brooklyn, New York, United States. Fundz records about 127 employees.
- Who are the decision-makers at Synchron?
- Fundz holds 2 contacts at Synchron. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Medical Equipment Manufacturing and Biotechnology around the same time
Companies in the same sectors as Synchron that raised within 45 days of this round, from Fundz verified event records.
- Grey Wolf Therapeutics raised $49M (Funding Round) on January 27, 2023.
- Inhibikase Therapeutics raised $4.2M (Seed) on January 27, 2023.
- ADARx Pharmaceuticals, Inc. raised $46M on January 26, 2023.
- HBM Alpha Therapeutics raised an undisclosed amount (Seed) on January 26, 2023.
- Streamex Corp. raised $234K (Seed) on January 25, 2023.
- Apexigen raised $2.8M (Seed) on January 24, 2023.
Who to call at Synchron, and when
A new round usually means Synchron is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Synchron raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Synchron, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Synchron. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Synchron raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Synchron raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.